Neupro (Rotigotine)

Neupro is a dopamine agonist used in movement‑disorder therapy. It provides symptomatic relief by stimulating central dopamine receptors.

• Parkinson's disease: improves motor function and reduces rigidity and bradykinesia.
• Restless Legs Syndrome: lessens the urge to move the legs and improves sleep quality.
• Motor fluctuations in Parkinson's disease: smooths on/off periods and reduces wearing‑off phenomena.

• Rotigotine penetrates the skin from the transdermal matrix and continuously stimulates dopamine D1, D2 and D3 receptors in the central nervous system. This dopaminergic activation compensates for the loss of endogenous dopamine in Parkinsonian pathways and modulates sensory‑motor circuits involved in restless leg symptoms.

Rotigotine may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Application site reaction: erythema, pruritus or edema at the patch site.
• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: sensation of light‑headedness, especially on standing.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Hallucinations: visual or auditory disturbances requiring medical review.
• Impulse control disorders: compulsive gambling, shopping or eating.
• Severe skin reactions: bullous dermatitis or Stevens‑Johnson‑like eruptions.

Before initiating Rotigotine therapy, consider the following safety measures.

• Dose titration: start with the lowest patch strength and increase as directed by the prescriber.
• Cardiovascular monitoring: observe blood pressure and orthostatic changes, especially in elderly patients.
• Psychiatric assessment: watch for new or worsening hallucinations, mood swings or suicidal thoughts.
• Skin inspection: regularly examine the patch site for irritation or allergic signs.
• Pregnancy and lactation: safety has not been established; avoid use unless clearly needed.
• Store at room temperature: keep in the original pouch, protect from light and moisture.

Rotigotine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• MAO‑B inhibitors: may potentiate dopaminergic effects and increase risk of hypertensive crisis.
• Antipsychotics: dopamine antagonists can reduce Rotigotine efficacy and precipitate worsening of Parkinsonian symptoms.

Moderate Interactions (Monitor Closely)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase Rotigotine plasma levels.
• Strong CYP2C19 inhibitors (e.g., omeprazole): may elevate exposure and side‑effect risk.
• Antihypertensive agents: additive blood‑pressure lowering effect may cause symptomatic hypotension.